Italo Poggesi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8655262/publications.pdf

Version: 2024-02-01

56 papers	1,831 citations	331670 21 h-index	276875 41 g-index
57 all docs	57 docs citations	57 times ranked	2461 citing authors

#	Article	IF	Citations
1	Predictive Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Kinetics in Xenograft Models after Administration of Anticancer Agents. Cancer Research, 2004, 64, 1094-1101.	0.9	432
2	Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors. Clinical Cancer Research, 2019, 25, 4888-4897.	7.0	181
3	Physiologically based pharmacokinetics (PBPK). Drug Metabolism Reviews, 2009, 41, 391-407.	3.6	108
4	Computational Models for Identifying Potential P-Glycoprotein Substrates and Inhibitors. Molecular Pharmaceutics, 2006, 3, 33-44.	4.6	106
5	Drug metabolism and pharmacokinetics. Drug Metabolism Reviews, 2009, 41, 344-390.	3.6	72
6	First Cdc7 Kinase Inhibitors: Pyrrolopyridinones as Potent and Orally Active Antitumor Agents. 2. Lead Discovery. Journal of Medicinal Chemistry, 2009, 52, 293-307.	6.4	72
7	Physiologicallyâ€Based Pharmacokinetic Modeling in Renal and Hepatic Impairment Populations: A Pharmaceutical Industry Perspective. Clinical Pharmacology and Therapeutics, 2021, 110, 297-310.	4.7	63
8	Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies. Cancer Chemotherapy and Pharmacology, 2015, 75, 111-121.	2.3	58
9	Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetateâ€“Treated Castration-Resistant Prostate Cancer Patients. Clinical Cancer Research, 2015, 21, 3170-3177.	7.0	57
10	Mathematical modeling of tumor growth and tumor growth inhibition in oncology drug development. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 1057-1069.	3.3	45
11	Population Pharmacokinetic Analysis of Abiraterone in Chemotherapy-NaÃ¯ve and Docetaxel-Treated Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical Pharmacokinetics, 2014, 53, 1149-1160.	3.5	43
12	Absolute bioavailability of reboxetine enantiomers and effect of gender on pharmacokinetics. , 1999, 20, 53-57.		41
13	A predictive model for exemestane pharmacokinetics/pharmacodynamics incorporating the effect of food and formulation. British Journal of Clinical Pharmacology, 2005, 59, 355-364.	2.4	37
14	Modeling of human tumor xenografts and dose rationale in oncology. Drug Discovery Today: Technologies, 2013, 10, e365-e372.	4.0	36
15	Predictive pharmacokineticâ€“pharmacodynamic modeling of tumor growth after administration of an anti-angiogenic agent, bevacizumab, as single-agent and combination therapy in tumor xenografts. Cancer Chemotherapy and Pharmacology, 2013, 71, 1147-1157.	2.3	30
16	Evaluation of a basic physiologically based pharmacokinetic model for simulating the first-time-in-animal study. European Journal of Pharmaceutical Sciences, 2007, 31, 190-201.	4.0	29
17	A Pharmacokinetic-Pharmacodynamic Model for Predicting Tumour Growth Inhibition in Mice: A Useful Tool in Oncology Drug Development. Basic and Clinical Pharmacology and Toxicology, 2005, 96, 265-268.	2.5	27
18	A Minimal Model of Tumor Growth Inhibition. IEEE Transactions on Biomedical Engineering, 2008, 55, 2683-2690.	4.2	26

#	Article	IF	Citations
19	Model-based approaches to increase efficiency of drug development in schizophrenia: a can't miss opportunity. Expert Opinion on Drug Discovery, 2009, 4, 837-856.	5.0	26
20	Hemodynamic effects of reboxetine in healthy male volunteers*. Clinical Pharmacology and Therapeutics, 1999, 66, 282-287.	4.7	25
21	Pharmacokinetics of Single-Dose Reboxetine in Volunteers with Renal Insufficiency. Journal of Clinical Pharmacology, 2000, 40, 482-487.	2.0	25
22	The effects of degree of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal women. Cancer Chemotherapy and Pharmacology, 2004, 53, 475-481.	2.3	23
23	Pharmacokinetics in special populations. Drug Metabolism Reviews, 2009, 41, 422-454.	3.6	20
24	Characterising the plasma-target occupancy relationship of the neurokinin antagonist GSK1144814 with PET. Journal of Psychopharmacology, 2014, 28, 244-253.	4.0	19
25	The successes and failures of physiologically based pharmacokinetic modeling: there is room for improvement. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 631-635.	3.3	19
26	Combined NK1 antagonism and serotonin reuptake inhibition: effects on emotional processing in humans. Journal of Psychopharmacology, 2013, 27, 435-443.	4.0	18
27	Modeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical Pharmacokinetics, 2017, 56, 55-63.	3.5	16
28	Some considerations on the predictions of pharmacokinetic alterations in subjects with liver disease. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 1397-1408.	3.3	15
29	Current mathematical models for cancer drug discovery. Expert Opinion on Drug Discovery, 2017, 12, 1-15.	5.0	15
30	High-performance liquid chromatographic assay of iomeprol in plasma and urine. Biomedical Applications, 1990, 525, 401-409.	1.7	11
31	A MODEL BASED ASSESSMENT OF REDISTRIBUTION DEPENDENT ELIMINATION AND BIOAVAILABILITY OF RIFABUTIN. , 1996, 17, 223-236.		11
32	Effect of Fluconazole and Itraconazole on the Pharmacokinetics of Erdafitinib in Healthy Adults: A Randomized, Open-Label, Drugâ€“Drug Interaction Study. European Journal of Drug Metabolism and Pharmacokinetics, 2020, 45, 101-111.	1.6	11
33	In vitro cell growth pharmacodynamic studies: a new nonparametric approach to determining the relative importance of drug concentration and treatment time. Cancer Chemotherapy and Pharmacology, 2003, 52, 507-513.	2.3	9
34	Clopidogrel, a CYP2C8 inhibitor, causes a clinically relevant increase in the systemic exposure to the active metabolite of selexipag in healthy subjects. British Journal of Clinical Pharmacology, 2021, 87, 119-128.	2.4	9
35	Re: Antitumor Efficacy Testing in Rodents. Journal of the National Cancer Institute, 2009, 101, 1592-1593.	6.3	8
36	Metabolism and disposition in rats, dogs, and humans of erdafitinib, an orally administered potent pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor. Xenobiotica, 2021, 51, 177-193.	1.1	8

#	Article	IF	Citations
37	Mathematical modeling of efficacy and safety for anticancer drugs clinical development. Expert Opinion on Drug Discovery, 2018, 13, 5-21.	5.0	7
38	Modeling approaches for reducing safety-related attrition in drug discovery and development: a review on myelotoxicity, immunotoxicity, cardiovascular toxicity, and liver toxicity. Expert Opinion on Drug Discovery, 2021, 16, 1365-1390.	5.0	7
39	Prediction of the drugâ€“drug interaction potential of the Î±1â€acid glycoprotein bound, CYP3A4/CYP2C9 metabolized oncology drug, erdafitinib. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 1107-1118.	2.5	6
40	Predicting human pharmacokinetics from preclinical data. Current Opinion in Drug Discovery & Development, 2004, 7, 100-11.	1.9	6
41	Development and validation of in silico models for estimating drug preformulation risk in PEG400/water and Tween80/water systems. European Journal of Pharmaceutical Sciences, 2007, 32, 169-181.	4.0	5
42	Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical trial. Investigational New Drugs, 2018, 36, 476-486.	2.6	5
43	Effect of Ponesimod Exposure on Total Lymphocyte Dynamics in Patients with Multiple Sclerosis. Clinical Pharmacokinetics, 2021, 60, 1239-1250.	3.5	5
44	An Exposure-Response Analysis of the Clinical Efficacy of Ponesimod in a Randomized Phase II Study in Patients with Multiple Sclerosis. Clinical Pharmacokinetics, 2021, 60, 1227-1237.	3.5	5
45	Persistence of increased levels of ribosomal gene activity in CHO-K1 cells treated in vitro with demethylating agents. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis, 1995, 348, 187-192.	1.1	4
46	Bayesian Population Modeling of Phase I Dose Escalation Studies: Gaussian Process Versus Parametric Approaches. IEEE Transactions on Biomedical Engineering, 2011, 58, 3156-3164.	4.2	4
47	Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial. Pharmaceutical Research, 2019, 36, 93.	3.5	4
48	Population Pharmacokinetic Analysis of Decitabine in Pediatric Patients With Acute Myeloid Leukemia. Journal of Clinical Pharmacology, 2019, 59, 668-676.	2.0	4
49	From pharmacokinetics to therapeutics. Drug Metabolism Reviews, 2009, 41, 455-474.	3.6	3
50	Prediction of the Effect of Renal Impairment on the Pharmacokinetics of New Drugs. Clinical Pharmacokinetics, 2018, 57, 505-514.	3.5	3
51	Abstract B19: Population pharmacokinetic-pharmacodynamic (PKPD) modeling of ibrutinib in patients with B-cell malignancies.. Clinical Cancer Research, 2015, 21, B19-B19.	7.0	3
52	A Quantitative Approach to the Prediction of Drug-Drug Interactions Mediated by Cytochrome P450 2C8 Inhibition. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 1345-1352.	3.3	3
53	Population pharmacokinetics of trabectedin in adolescent patients with cancer. Cancer Chemotherapy and Pharmacology, 2019, 84, 707-717.	2.3	2
54	A Population Pharmacokinetic Model of Macitentan and Its Active Metabolite Aprocitentan in Healthy Volunteers and Patients with Pulmonary Arterial Hypertension. Clinical Pharmacokinetics, 2021, 60, 1605-1619.	3.5	2

#	Article	IF	Citations
55	Biomarker- versus drug-driven tumor growth inhibition models: an equivalence analysis. Journal of Pharmacokinetics and Pharmacodynamics, 2015, 42, 611-626.	1.8	1
56	Systemic Exposure of Rituximab Increased By Ibrutinib: Pharmacokinetic Results from the Helios Trial. Blood, 2016, 128, 4403-4403.	1.4	0